A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 47/48 (2006.01) C07K 16/28 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2180834
This invention relates to the development of agents and methods for treating tumour cells. More particularly, it is concerned with antibodies against the epidermal growth factor receptor (EGFR), which have been found to exhibit an antitumour effect, inducing terminal differentiation in tumour cells, especially those which are characterised by over-expressing EGFR. Included in the invention are these antibodies and their functional equivalents, mutants and derivatives. The antibodies may be murine (rat or mouse), but preferably have framework regions and or constant regions based on or derived from human antibodies. The present invention also discloses that fragments of these antibodies (eg Fabs) can retain the properties of the complete antibody. The antibodies are useful, e.g. in treating or detecting tumour cells and in targeting therapies.
L'invention concerne la mise en application d'agents et de procédés de traitement de cellules tumorales. Elle concerne, plus particulièrement, des anticorps contre le récepteur du facteur de croissance épidermique (EGFR) qui se sont avérés présenter un effet antitumeur, provoquant une différentiation terminale dans des cellules tumorales, particulièrement celles qui sont caractérisées par un DGFR à expression excessive. L'invention comprend également lesdits anticorps et leurs équivalents fonctionnels, mutants ou dérivés. Les anticorps peuvent être murins (rat ou souris) mais possèdent de préférence des régions structurelles et/ou des régions constantes à base d'anticorps humains ou dérivées de ceux-ci. Elle concerne également la capacité de conservation des propriétés de l'anticorps complet que possèdent des fragments desdits anticorps (par exemple, Fabs). Les anticorps sont efficaces dans le traitement ou la détection de cellules tumorales et dans des thérapies de ciblage.
Dean Christopher John
Modjtahedi Helmout
Bereskin & Parr
Cancer Research Campaign Technology Limited
LandOfFree
Antibodies to egf receptor and their antitumour effect does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to egf receptor and their antitumour effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to egf receptor and their antitumour effect will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1675799